AccApplic will facilitate the activities of the European accelerator communities in the development of accelerators for applications in industry, healthcare, energy production and security. It will assess the use of novel technology, particularly that developed for accelerator infrastructure used for academic research, for a variety of applications. This will involve close collaboration with potential users of the technology being studied. Amongst the infrastructure that already exists or is being developed that will be exploited are Linac 4 and the SPL at CERN, the Front End Test Stand in STFC, the European Spallation Source in Sweden, a number of cyclotrons and electrostatic accelerators, the EMMA FFAG in STFC and targets developed at PSI, STFC and elsewhere. Applications that will be investigated include cancer therapy with X- rays, protons, ions and neutrons (in the form of Boron Neutron Capture Therapy), ion implantation, the production of Molybdenum 99, cargo container screening, the production of PET isotopes and Accelerator Driven Systems for nuclear power production and waste transmutation. It will also be possible to include other applications that are proposed or identified during the work. The potential participants in the network will include many of the major accelerator laboratories in Europe and a number of companies.
To meet these goals, the tasks will organize annual workshops and topical mini-workshops, participate in related events in other projects, support the exchange of experts, propose and follow-up beam experiment results to improve knowledge and will have a large involvement from students and fellows. The results will be disseminated by journal publications and by seminars at partner institutes, conferences, and European universities, and via web documentation, e.g. web databases. The participation shall be largely open both inside and outside of the consortium.
EuCARD-2 is co-funded by the partners and the European Commission under Capacities 7th Framework Programme, Grant Agreement 312453.